信达生物制药（苏州）有限公司 Innovent BiologicsInc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA 2024-05-28 08:00
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease 2024-05-21 08:55
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC) 2024-05-20 08:20
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints 2024-05-09 08:00
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer 2024-05-07 08:12
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO) 2024-04-30 12:30
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting 2024-04-25 10:02
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO) 2024-04-16 08:00
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting 2024-04-08 08:00
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status 2024-04-02 13:00
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy 2024-03-27 08:00
Innovent Announces 2023 Annual Results and Business Updates 2024-03-20 19:44
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD) 2024-03-19 08:00
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting 2024-03-12 08:00
Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 2024-03-07 11:53
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer 2024-03-05 13:35
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia 2024-03-01 08:00
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA 2024-02-20 08:22
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China 2024-02-07 16:35
Innovent Announces Retirement of CFO and Appointment of New CFO 2024-02-05 16:45
1 2 3 4 5 17